Compounds of formula (I):
1
wherein B, Y, R
3
, R
24
, R
2
, R
1
and R
C
are defined herein. The compounds are useful as inhibitors of HCV NS3 protease.
Compounds of formula (I):
1
wherein B, X, R
3
, R
21
, R
22
, R
1
and R
c
are defined herein. The compounds are useful as inhibitors of HCV NS3 protease.
Compounds of formula (I):
wherein B, X, R
3
, L
0
, L
1
, L
2
, R
2
, R
1
and R
C
are defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.
PROCESS FOR PREPARING ACYCLIC HCV PROTEASE INHIBITORS
申请人:BUSACCA Carl Alan
公开号:US20090124809A1
公开(公告)日:2009-05-14
Disclosed are highly convergent processes for preparing compounds of formula (I), which compounds are potent active agents for the treatment of hepatitis C virus (HCV) infection:
The disclosed processes use S
N
Ar-type coupling reactions between peptidic compounds having a hydroxyproline moiety of the following formula:
and halogenated or sulfonated bromoquinoline compounds.